Update on FDA Review of VTAMA - Business Wire
4 days ago · JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and ...
Investors Heavily Search Organon & Co. (OGN): Here is What You …
5 days ago · For the current quarter, Organon is expected to post earnings of $0.98 per share, indicating a change of +11.4% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.1% over the ...
News - Organon
Sep 18, 2024 · Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%. October 09, 2024. Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024. September 30, 2024.
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the …
4 days ago · Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) extended by three months the target action date of its review of the supplemental New Drug Application (sNDA) for VTAMA ® (tapinarof) cream, 1% as a …
Organon & Co. Reports Strong Third Quarter 2024 Results
Nov 1, 2024 · Organon’s guidance for the full year 2024 revenue has been narrowed to a range of $6.375 billion to $6.425 billion, with an adjusted EBITDA margin expected between 30.0% and 31.0%. The company ...
Organon to Acquire Dermavant including its Innovative …
Sep 18, 2024 · Organon has agreed to acquire Dermavant for aggregate consideration of up to approximately $1.2 billion, with an upfront payment of $175 million and a $75 million
Organon & Co. (OGN) Latest Stock News & Headlines - Yahoo …
Get the latest Organon & Co. (OGN) stock news and headlines to help you in your trading and investing decisions.
Organon affirms 2023 revenue and Adjusted EBITDA guidance …
Jan 8, 2024 · For full year 2023, the company is affirming prior revenue and Adjusted EBITDA margin guidance in the ranges of $6.15 billion to $6.25 billion and 30.5% to 31.5%, respectively. Full year 2023 free...
Organon: FDA Extends Vtama Atopic-Dermatitis Review to March
5 days ago · Organon said that as a result of the delay, it now expects Vtama to contribute about $125 million in revenue next year, with the Dermavant deal reducing its 2025 adjusted earnings before interest ...
Organon & Co. (OGN) Stock Price, Quote, News & Analysis - Seeking Alpha
A high-level overview of Organon & Co. (OGN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.